NMRA — Neumora Therapeutics, Inc.
Is NMRA overbought or oversold? Here is the current MarketMoodz read.
Neumora Therapeutics, Inc. (NMRA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.50. The rating moved from Strong Oversold to Oversold on October 2, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$0.50
- Last changeMoved from Strong Oversold to Oversold on October 2, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Neumora Therapeutics, Inc. (NMRA) is primarily a pipeline‑driven small‑cap biotech whose equity value depends on clinical progress, financing cadence and partnership activity. Available information is limited (no recent EDGAR summary provided), increasing uncertainty about cash runway and near‑term dilution risk. Key near‑term catalysts would be clinical data readouts, corporate partnerships or financing executed at acceptable terms. Major challenges include trial execution risk, policy/reimbursement pressure that could limit pricing, and competition. Given heightened volatility and funding sensitivity for micro‑cap biotechs, positions should consider time horizon, tolerance for dilution, and event‑driven risk.
Key factors
- Early‑stage biotech with product‑pipeline value as primary driver of equity returns rather than current revenues
- Limited public financial disclosure in provided data (no recent EDGAR summary), increasing uncertainty around cash runway and dilution risk
- Sector backdrop: risk‑off market tone and cooling IPO window reduce appetite for speculative healthcare names
- Positive sector signal from late‑stage biologics and rare‑disease wins that can lift specialty pharma sentiment if Neumora reports supportive clinical data
- Policy pressure from Medicare drug‑price negotiation introduces pricing/access uncertainty across therapeutics, especially for high‑priced specialty drugs
- Low trading liquidity and micro‑cap price sensitivity increase volatility and potential for outsized moves on news
Risks
- Clinical trial failures or disappointing data readouts that materially impair pipeline valuation
- Near‑term cash‑burn and financing needs leading to equity dilution under unfavorable market conditions
- Adverse policy or reimbursement developments (Medicare/IRA) compressing future pricing and commercial prospects
- Competitive displacement from better‑funded rivals or new modality entrants in neurology/psychiatry therapeutic space
- Market risk‑off periods and weak healthcare IPO/financing windows limiting access to capital and pressuring share price
- Low liquidity increasing bid‑ask spreads, price gaps, and execution risk for investors
See today's live rating, score and targets
Members see the live hourly rating for NMRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.